

09.12.2020

09:00 - 20:00 **Type: Poster Display session** **e-Poster Display**
Title: e-Poster Display Session

09:00 - 09:00 **Biomarker development**

09:00 - 09:00 **2P - Lung Immune Prognostic Index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours**

E. Auclin¹, P. Vuagnat², C. Smolenschi², J. Taieb¹, J. Adeva Alfonso³, L. Nebot², M. Garcia De Herreros⁴, R. Vidal Tocino⁵, F. Longo⁶, Y. El Dakdouki², P. Martin Romano⁷, E. Castanon Alvarez⁸, R. Garcia-Carbonero³, L. Gaba Garcia⁴, T. Sauri Nadal⁴, H. Oliveres⁹, B. Besse², C. Massard¹⁰, L. Mezquita⁴, A. Hollebecque², ¹Hopital European George Pompidou, Paris, FR, ²Institut Gustave Roussy, Villejuif, FR, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁵IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ⁶Hospital Universitario Ramon y Cajal, Madrid, ES, ⁷Gustave Roussy, Villejuif, FR, ⁸Persan Farma, Las Palmas de Gran Canaria, ES, ⁹Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES, ¹⁰Gustave Roussy - Cancer Campus, Villejuif, FR

09:00 - 09:00 **3P - Association between inflammation index and nutritional status and the effectiveness of immunotherapy in NSCLC treatment.**

S. Tolu¹, F. Balconi², N. Liscia², D. Spanu¹, M. Persano², G. Pinna³, M. Dubois³, G. Saba³, V. Impera³, S. Mariani³, C. Donisi², A. Pretta², A. Pireddu¹, F. Musio³, M. Migliari³, R. Piredda³, M. Scartozzi⁴, C. Madeddu³, ¹University of Cagliari, Cagliari, IT, ²Azienda Ospedaliero Universitaria di Cagliari - Ospedale Civile, Cagliari, IT, ³Azienda Ospedaliero Universitaria di Cagliari, Monserrato, IT, ⁴Policlinico Universitario Monserrato, Monserrato, IT

09:00 - 09:00 **4P - IgM-Rheumatoid Factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+ T-cells.**

A. Ugolini¹, I. Zizzari², F. Ceccarelli³, A. Botticelli³, T. Colasanti³, L. Strigari⁴, A. Rughetti¹, H. Rahimi¹, F. Conti³, G. Valesini³, P. Marchetti³, M. Nuti¹, ¹Sapienza - Università di Roma, Rome, IT, ²Sapienza Università di Roma, Rome, IT, ³Policlinico Umberto I, Rome, IT, ⁴Ospedale Sant'Orsola Malpighi, Rome, IT

09:00 - 09:00 **5P - Uncovering the evolution of Glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers**

N. Tatari¹, S. Khan², J. Livingstone³, C. Venugopal¹, J. Chan⁴, C. Hawkins⁵, J. Provias⁶, J. Lu⁶, K. Ask⁶, T. Kislinger³, S. Singh¹, ¹Stem Cell and Cancer Research Institute - McMaster University, Hamilton, CA, ²Princess Margaret Cancer Centre, University health Network, Toronto, CA, ³Princess Margaret Cancer Centre, University health Network, University of Toronto, Toronto, CA, ⁴University of Calgary, Calgary, CA, ⁵University of Toronto, Toronto, CA, ⁶McMaster University, Hamilton, CA

- 09:00 - 09:00 **6P - Role of inflammatory cytokines in distant metastasis of non-small cell lung cancer**
O. Savelieva¹, D. Pismenny¹, L. Tashireva², M. Zavyalova³, V. Perelmuter², ¹Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RU, ²Cancer Research Institute - Tomsk National Research Medical Center, Tomsk, RU, ³Siberian State Medical University, Tomsk, RU
- 09:00 - 09:00 **7P - Peripheral Blood-Based Biomarkers of Prognosis and Treatment Response in Patients with Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors**
I. Tourkantonis¹, D. Grapsa², A. Charpidou¹, I. Gkiozos², H. Gogas³, D. Psyrri⁴, K. Syrigos⁴, ¹University of Athens, Sotiria General Chest Diseases Hospital, Athens, GR, ²National and Kapodistrian University of Athens, Athens, GR, ³Laiko General Hospital of Athens, Athens, GR, ⁴Medical School, National and Kapodistrian University of Athens, Athens, GR
- 09:00 - 09:00 **8P - Immune cell subsets in peripheral blood are associated with primary resistance to immunotherapy as frontline treatment in NSCLC**
H. Arasanz¹, M. Zuazo², L. Chocarro², A.I. Bocanegra Gondan², M. Martínez-Aguillo¹, I. Morilla¹, G. Fernández-Hinojal², E. Blanco², L. Teijeira¹, P. Morente², I. Pedroarena², R. Vera¹, G. Kochan², D. Escors², ¹Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES, ²Navarrabiomed, Pamplona, ES
- 09:00 - 09:00 **9P - Circulating tumor cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)**
J. Menis¹, P. Bironzo², G. Radj³, L. Greillier⁴, I. Monnet⁵, L. Livi⁶, R. Young⁷, C. Decroisette⁸, N. Cloarec⁹, G. Robinet¹⁰, R. Schott¹¹, R. Califano¹², F. De Marinis¹³, M. Mauer¹⁴, A. Pochesci¹⁴, M. Silva¹⁵, C. Caramella¹⁶, A.-M. Dingemans¹⁷, C. Dive¹⁸, B. Besse¹⁹, ¹Istituto Oncologico Veneto IRCCS, Padova, IT, ²Ospedale S. Luigi Gonzaga - Università Di Torino, Torino, IT, ³Centre Francois Baclesse (CLCC), Caen, FR, ⁴Aix Marseille Univ, APHM, Marseille, FR, ⁵Chi De Creteil, Creteil, FR, ⁶University of Florence - Careggi Hospital, Firenze, IT, ⁷Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ⁸Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, ⁹Centre Hospitalier d'Avignon, Avignon, FR, ¹⁰CHU de Brest, Brest, FR, ¹¹Institut de Cancerologie (ICANS), Strasbourg, FR, ¹²The Christie NHS Foundation Trust and University of Manchester, Manchester, GB, ¹³Istituto Oncologico Europeo, Milan, IT, ¹⁴EORTC Headquarters, Bruxelles, BE, ¹⁵University of Parma, Parma, IT, ¹⁶Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, FR, ¹⁷Erasmus MC, Rotterdam, NL, ¹⁸Cancer Research UK Manchester Institute Cancer Biomarker Centre, Manchester, GB, ¹⁹Institut Gustave Roussy, Villejuif, FR
- 09:00 - 09:00 **10P - Genomic profiles of CD47 in breast tumors predict outcome and are associated with immune activation and enrichment of pro-tumoral macrophage markers**
A. Ocaña¹, M.D.M. Noblejas Lopez², M. Baliu-Piqué¹, C. Nieto-Jiménez³, F.J. Cimas⁴, E.C. Morafraille¹, A. Pandiella³, Á.L. Corbí⁵, B. Györffy⁶, ¹Hospital Clínico San Carlos (HCSC), Madrid, ES, ²Complejo Hospitalario Universitario de Albacete, Albacete, ES, ³Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Salamanca, ES, ⁴Translational

Research Unit, Albacete, ES, ⁵Centro de Investigaciones Biológicas (CIB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, ES, ⁶Semmelweis University, Budapest, HU

- 09:00 - 09:00 **12P - The correlation between non-coding RNA and response rate to immune-checkpoint inhibitors.**
D. Shek¹, S. Read², A. Nagrial³, M. Carlino⁴, J. George⁵, B. Gao⁶, G. Ahlenstiel²,
¹Western Sydney University - School of Medicine, Campbelltown, AU, ²Western Sydney University - School of Medicine, Blacktown, AU, ³Westmead Hospital, Westmead, AU, ⁴Melanoma Institute Australia, Wollstonecraft, AU, ⁵The University of Sydney, Westmead, AU, ⁶Blacktown Hospital, Blacktown, AU
- 09:00 - 09:00 **13P - PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics**
T. Powles¹, M. Van Der Heijden², A. Balar³, P. O'Donnell⁴, C. Massard⁵, J. Walker⁶, A. Gupta⁷, N. Angra⁸, J. Cairns⁹, B. Turriziani⁹, M. Rebelatto¹⁰, M. Scott⁹, S. Wildsmith⁹,
¹St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ²Netherlands Cancer Institute, Amsterdam, NL, ³NYU Langone Medical Center, New York, US, ⁴University of Chicago Medicine, Chicago, US, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶AstraZeneca UK, Royston, GB, ⁷AstraZeneca USA, Gaithersburg, US, ⁸AstraZeneca, Gaithersburg, US, ⁹AstraZeneca, Cambridge, GB, ¹⁰AstraZeneca, Gaithersburg, US
- 09:00 - 09:00 **14P - High CMTM6 and PD-L1 co-expression predict metastasis and poor prognosis in esophageal squamous cell carcinoma**
Y. Luo, C. Zhang, Z. Zhang, G. Zhang, L. Xue, Q. Zeng, Q. Xue, S. Gao, N. Sun, J. He, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN
- 09:00 - 09:00 **15P - Tumor PD-L1 expression and blood biomarkers of activity of adaptive immunity and tumor microenvironment in patients with solid tumors**
A. Malkova¹, R. Orlova², N. Zhukova³, V. Sharoyko¹, E. Kaledina⁴, A. Gubal¹, ¹Saint-Petersburg state university, Saint-Petersburg, RU, ²St. Petersburg State University, Medical Faculty, Saint-Petersburg, RU, ³City Clinical Oncology Dispensary, Saint-Petersburg, RU, ⁴St. Petersburg State University (SPSU), Saint-Petersburg, RU
- 09:00 - 09:00 **16P - PD-1/PD-L1 expression in Uveal Melanoma: Prognostic significance with tumor-infiltrating lymphocytes and clinicopathological parameters**
L. Singh¹, M. Singh¹, M. Rizvi², S. Kashyap³, ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²Jamia Millia Islamia, New Delhi, IN, ³All India Institute of Medical Sciences, New Delhi, IN
- 09:00 - 09:00 **17P - Effects of tumor mutation burden on the antigen presentation pathway**
E. Garcia-Rivera¹, J. Park¹, C. Truntzer², F. Ghiringhelli², A. Mansfield¹, ¹Mayo Clinic, Rochester, US, ²Platform of Transfer in Biology of Cancer, Georges Francois Leclerc Cancer Center, Dijon, FR
- 09:00 - 09:00 **18P - Influence of local immunity on the prognosis of gastric cancer.**

G. Khakimova, N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU

- 09:00 - 09:00 **19P - Tumor microenvironment and radiomics landscape associated with survival and prediction of immunotherapy in patients with cancer**
W. Zhang¹, A. Li¹, Y. Chen², Q. Ou³, W. Ren³, Z. He³, Y. Yu³, H. Yao³, ¹Guangdong Medical University, Zhanjiang, CN, ²The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ³Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN
- 09:00 - 09:00 **20P - Quantitative whole slide assessment of CD8+ tumor-infiltrating lymphocytes in small cell esophageal carcinoma in relation to clinical outcome**
Z. Zhang¹, C. Zhang², G. Zhang³, L. Xue³, Q. Zeng³, L. Yue³, Q. Xue³, S. Gao³, N. Sun³, J. He³, ¹CAMS-PUMC - Chinese Academy of Medical Sciences and Peking Union Medical College - Dongdan Campus, Beijing, CN, ²Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 09:00 - 09:00 **21P - Characteristics of the lymphocytic infiltrate in breast cancer**
W. Ben Kridis¹, L. Bouzidi², S. Charfi², H. Triki³, B. Cherif³, A. Rebai³, K. Chaaben², T. Boudawara², J. Daoud², A. Khanfir², ¹University of Sfax - Hopital Habib Bourguiba, Sfax, TN, ²University of Sfax - Hopital Habib Bourguiba, sfax, TN, ³Center of Biotechnology of Sfax, sfax, TN
- 09:00 - 09:00 **22P - Dynamics of indicators of the immune status in patients with metastatic solid tumors on the background of stereotactic ablative radiation therapy**
A. Zozulya¹, I. Baldueva², S. Novikov¹, D. Girdyuk¹, N. Emelyanova¹, E. Tyuryaeva¹, E. Fedosova¹, P. Antipov¹, A. Arseniev¹, S. Kanaev¹, A. Belyaev¹, ¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ²GBUZ St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), Saint-Petersburg, RU
- 09:00 - 09:00 **Cell therapy**
- 09:00 - 09:00 **25P - Improving efficacy and reducing toxicity of anti-PD-L1 treatment - T cells as delivery vehicles for anti-PD-L1 blocking nanobodies**
P.-F. Petit, J. Zhu, B. Van Den Eynde, Ludwig Institute for Cancer Research, Brussels, BE
- 09:00 - 09:00 **26P - Cellulose Beads Prepared in Deep Eutectic Solvent Function as Carrier and Cytoprotective Encapsulation Matrix for CAR-T Cells in T-Cell Therapy against Glioblastoma Cells**
S. Vuoti¹, M. Saari², K. Narasimha², K. Reinikainen², ¹University of Jyväskylä, Jyväskylä, FI, ²Chembrain LTD, Kauhava, FI
- 09:00 - 09:00 **27P - Methodology for identification of clinically relevant targets for TCR-immunotherapy in hepatocellular carcinoma**

P. Maravelia¹, A. Potti¹, D.S. Silva¹, T. Sekine¹, K. Healy², M. Chrobok¹, C. Jorns², M. Sällberg¹, M. Buggert¹, A. Pasetto¹, ¹Karolinska Institutet, Huddinge, SE, ²Karolinska Institutet, Stockholm, SE

- 09:00 - 09:00 **28P - Helping the killers: innovative cancer immunotherapy harnessing quasi-universal tumor antigen-specific CD4 T cells**
- M. Saillard¹, A. Cachot¹, A. Rockinger¹, P. Guillaume¹, J. Schmidt¹, A. Harari¹, C. Jandus², P. Romero³, ¹UNIL - Université de Lausanne - CHUV, Lausanne, CH, ²Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, CH, ³Ludwig Center for Cancer Research of the UNIL, Epalinges, CH
- 09:00 - 09:00 **29P - ALLELE Study: A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) after Failure of Rituximab or Rituximab and Chemotherapy**
- N. Worel¹, J.A. Perez-Simon², P. Barba³, D. Dierickx⁴, M. Hiremath⁵, W. Ye⁵, L. Gamelin⁵, W. Navarro⁵, S. Choquet⁶, ¹Medical University Vienna, Vienna, AT, ²Universidad de Sevilla, Sevilla, ES, ³Hospital Universitari Vall d'Hebrón Universitat Autònoma de Barcelona, Barcelona, ES, ⁴University Hospitals Leuven, Leuven, BE, ⁵Atara Biotherapeutics, San Francisco, US, ⁶APHP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, FR
- 09:00 - 09:00 **Clinical practice**
- 09:00 - 09:00 **31P - Integrated Safety Analysis of Anti-Programmed Cell Death-1 (PD-1) Antibody Penpulimab in Advanced Solid tumor or Lymphoma.**
- N. Xu¹, B. Han², S. Jiao³, C. Hu⁴, A. Mislav⁵, J. Coward⁶, A. Cooper⁷, C. Underhill⁸, Y. Xia⁹, D. Xia¹⁰, X. Jin¹¹, Z. Wang¹¹, B. Li⁹, ¹The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou, CN, ²Shanghai Chest Hospital, Shanghai, CN, ³Chinese PLA General Hospital, Beijing, CN, ⁴Shanghai Cancer center, Shanghai, CN, ⁵Adelaide Cancer Centre, Kurralt Park, AU, ⁶Icon Cancer Centre, Brisbane, AU, ⁷University of Western Sydney School of Medicine, Liverpool, AU, ⁸Albury-Wodonga Regional Cancer Centre, Albury-Wodonga, AU, ⁹Biopharma, Inc., Zhongshan, CN, ¹⁰Inc., Zhongshan, CN, ¹¹Biopharma, Inc., Shanghai, CN
- 09:00 - 09:00 **32P - Low Immunogenicity and Favorable Safety Seen with Novel Regimen of Tremelimumab (T) Plus Durvalumab (D) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (uHCC)**
- R.K. Kelley¹, A. Negro², C. Chen³, S. Ali⁴, N. Standifer³, M. Watras⁵, B. Evans², G. Abou-Alfa⁶, ¹UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, ²AstraZeneca USA, Gaithersburg, US, ³AstraZeneca, San Francisco, US, ⁴AstraZeneca, Cambridge, GB, ⁵AstraZeneca, Warsaw, PL, ⁶Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 09:00 - 09:00 **34P - Patient Characteristics and Treatment Patterns in Advanced Renal Cell Carcinoma (aRCC) Following Introduction of New Therapies**

Y. Zakharia¹, G. Zanotti², F. Liu³, R. Levin², A. Meche², ¹University of Iowa, Iowa City, US, ²Pfizer Inc - USA, New York, US, ³EMD Serono, Rockland, US

09:00 - 09:00 **35P - Toxicity and safety of novel immuno-oncology (IO) treatments after prior immune checkpoint inhibitors (ICIs) exposure**

A. Valdivia¹, A. Hernando², O. Saavedra³, R. Berché², I. Braña¹, I. Matos Garcia³, A. Ázaro³, M. Vieito Villar¹, G. Alonso³, V. Galvão³, H.K. Oberoi Oberoi⁴, N. Wornham³, L. Fariñas Madrid¹, N. Mulet Margalef⁵, R. Morales Barrera¹, P. Iranzo Gomez¹, E. Muñoz Couselo¹, J. Tabernero⁶, R. Dienstmann³, E. Garralda², ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Hospital Clínic of Barcelona, Barcelona, ES, ⁵Institut Català d'Oncologia-Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ⁶Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES

09:00 - 09:00 **36P - Progression-free survival as a surrogate for overall survival in trials of immune checkpoint inhibitors in pancancer evaluated by RECIST 1.1**

L. Lin¹, H. Xu², J. Ding², T. Qin², M. Xu², J. Shen², W. Jiang², J. Wang², D. Cheng², Z. Li², H. Hu², Y. Yu², H. Yao², ¹2nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, CN, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN

09:00 - 09:00 **37P - First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis**

J. Breeschoten¹, M. Wouters¹, D. Hilarius², J. Haanen³, C. Blank³, M. Aarts⁴, F. Van Den Berkmoortel⁵, J.W. De Groot⁶, G. Hospers⁷, E. Kapiteijn⁸, D. Piersma⁹, R. Van Rijn¹⁰, K. Suijkerbuijk¹¹, W. Blokkx¹², A. Ten Tije¹³, A. Van Der Veldt¹⁴, G. Vreugdenhil¹⁵, M. Boers-Sonderen¹⁶, A. Van Den Eertwegh¹⁷, ¹DICA - Dutch Institute for Clinical Auditing, Leiden, NL, ²Rodekruis Ziekenhuis Beverwijk, Beverwijk, NL, ³Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, ⁴Atrium Medisch Centrum, Maastricht, NL, ⁵Zuyderland Medical Center, Heerlen, NL, ⁶Isala ziekenhuis, Zwolle, NL, ⁷UMCG - University Medical Center Groningen, Groningen, NL, ⁸Leiden University Medical Center (LUMC), Leiden, NL, ⁹Medisch Spectrum Twente (MST) - Radiological Examination (only), Enschede, NL, ¹⁰University Hospital Groningen (UMCG), Groningen, NL, ¹¹UMC-University Medical Center Utrecht, Utrecht, NL, ¹²University Medical Center Utrecht, Utrecht, NL, ¹³Amphia Ziekenhuis-location Molengracht, Breda, NL, ¹⁴Erasmus University Medical Center, Rotterdam, NL, ¹⁵Maxima Medisch Centrum -Veldhoven, Veldhoven, NL, ¹⁶Radboud University Medical Centre Nijmegen, Nijmegen, NL, ¹⁷Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

09:00 - 09:00 **38P - Predicting objective response rate (ORR) in immune checkpoint inhibitor (ICI) therapies with machine learning (ML) by combining clinical and patient-reported data**

S. Iivanainen¹, J. Esktorn², H. Virtanen², L. Lang², V. Kataja², J. Koivunen¹, ¹Oulu University Hospital, Oulu, FI, ²Kaiku Health Oy, Helsinki, FI

09:00 - 09:00

39P - The Lung Immune Prognostic Index (LIPI) as prognostic factor in solid tumors - the experience of a community hospital

M. Vitorino¹, T. Tomás², S. De Almeida², M. Honório³, M. Silva³, ¹Hospital Professor Doutor Fernando Fonseca EPE (Hospital Amadora/Sintra), Lisbon, PT, ²Hospital Prof. Dr Fernando Fonseca E.P.E (Amadora/Sintra), Amadora, PT, ³Hospital Prof. Dr Fernando Fonseca EPE (Hospital Amadora/Sintra), Amadora, PT

09:00 - 09:00 **40P - Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer**

R. Cunha¹, M. Fernandes², S. Abreu², C. Oliveira², J. Dias², S. Alves², A. Rodrigues², J. Oliveira², M.I. Pousa³, M. Soares², I. Azevedo², ¹Hospital Espírito Santo, EPE - Évora, Evora, PT, ²Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E, Porto, PT, ³IPO Porto, Algés, PT

09:00 - 09:00 **41P - Cardiotoxicity of immune checkpoint inhibitors: a meta-analysis of randomized clinical trials**

E. Agostinetti¹, D. Eiger¹, M. Lambertini², M. Ceppi², M. Bruzzzone², N. Pondé³, C. Plummer⁴, A. Awada⁵, M. Piccart⁵, E. De Azambuja¹, ¹Institut Jules Bordet, Brussels, BE, ²IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ³AC Camargo Cancer Center, Sao Paulo, BR, ⁴Newcastle University, Newcastle upon Tyne, GB, ⁵Institute Jules Bordet, Brussels, BE

09:00 - 09:00 **42P - Pleural effusion is a negative prognostic factor for immunotherapy in non small cell lung cancer (NSCLC): the PLUIE study.**

N. Epailard¹, J.C. Benitez², T. Gorria³, E. Fabre-Guillevin⁴, M. Ruidavets⁵, R. Reyes⁵, D. Planchard⁶, N. Reguart Aransay⁵, B. Besse⁶, L. Mezquita⁵, E. Auclin⁷, ¹Hôpital de la Salpêtrière, Paris, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Hospital Clinic, Barcelona, ES, ⁴European George Pompidou Hospital - APHP, Paris, FR, ⁵Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁶Institut Gustave Roussy, Villejuif, FR, ⁷Hopital Européen Georges Pompidou, Paris, FR

09:00 - 09:00 **43P - Ocular adverse events due to PD-1 and PD-L1 checkpoint inhibitors: a retrospective review of FDA adverse events reporting system (FAERS)**

Y. Sahu¹, J. Ensor², E. Burns³, G. Sahu⁴, S. Iyer⁵, K. Anand⁶, ¹Safdarjung hospital, new delhi, IN, ²Houston methodist research institute, Houston, US, ³Houston Methodist Hospital, houston, US, ⁴Creighton University School of Medicine, North Platte, US, ⁵UT MD Anderson Cancer Center, Houston, US, ⁶Great Plains Health, North Platte, US

09:00 - 09:00 **44P - The hematologic toxicities of chemo-immunotherapy compared to chemotherapy alone: a systematic review and meta-analysis**

D. Eiger¹, E. Agostinetti¹, R. Caparica¹, M.A. Franzoi¹, M. Brandão¹, L. Buisseret², A. De Caluwé¹, D. Gimenes³, S. Simon³, N. Pondé⁴, E. De Azambuja², ¹Institute Jules Bordet, Brussels, BE, ²Institut Jules Bordet, Brussels, BE, ³Grupo Oncoclinicas do Brasil e Centro Paulista de Oncologia, Sao Paulo, BR, ⁴AC Camargo Cancer Center, Sao Paulo, BR

09:00 - 09:00 **45P - Immune-related adverse events: spectrum and clinical features in the real world**

I. Vieira, S. Pinelas, C. Gaspar, J. Dinis, J. Oliveira, Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E, Porto, PT

- 09:00 - 09:00 **46P - [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FDG-PET/CT) in patients treated with immune checkpoint inhibitors (ICI) for microsatellite instability-high metastatic colorectal cancer (MSI mCRC)**
- T. Pudlarz¹, F. Montravers², M.-L. Garcia-Larnicol³, E. Kempf⁴, J. Bennouna⁵, C. De La Fouchardière⁶, D. Tougeron⁷, C. Borg⁸, T. Mazard⁹, B. Chibaudel¹⁰, Y. Parc¹, M. Svrcek¹, Y. Menu¹, R. Cohen¹, T. Andre¹, ¹Hôpital Saint-Antoine, Paris, FR, ²Hôpital Tenon, PARIS, FR, ³Multidisciplinary Group in Oncology (GERCOR), Paris, FR, ⁴Assistance Publique - Hopitaux De Paris, Creteil, FR, ⁵CHU du Nantes - Hôtel-Dieu, Nantes, FR, ⁶Centre Léon Bérard, Lyon, FR, ⁷Poitiers University Hospital, Poitiers, FR, ⁸CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ⁹ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹⁰IHFB SITE KLEBER, FR
- 09:00 - 09:00 **47P - Radiological patterns of tumor progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.**
- E. Guiard¹, C. Baldini², C. Pobel², P. Martin-Romano², S. Champiat³, A. Hollebecque², S. Postel-Vinay², A. Varga², R. Bahleda⁴, A. Gazzah², L. Verlingue², A. Geraud², M. Ningarhari², E. Angevin⁴, J.-M. Michot², V. Ribrag², A. Marabelle², J.-C. Soria⁵, C. Massard⁴, S. Ammari³, ¹CHU de Caen - Hopital Cote de Nacre, Caen, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵Université Paris Saclay, Villejuif, FR
- 09:00 - 09:00 **48P - Impact of 12 months of immunotherapy for metastatic cancer patients on oncology workload**
- V. Andreotti¹, M. Cinausero², S.K. Garattini², L. Bortot², L. Palmero², F. Valent¹, C. Riosa², D. Iacono¹, M. Casagrande², K. Rihawi¹, M. Macerelli¹, A.M. Minisini¹, G. Fasola¹, ¹Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Presidio Ospedaliero Universitario "Santa Maria della Misericordia", Udine, IT, ²Azienda Sanitaria Universitaria Friuli Centrale, Udine, IT
- 09:00 - 09:00 **49P - Discontinuation of immune checkpoint inhibitors in patients with relapsed and refractory classical Hodgkin lymphoma**
- L. Fedorova, K. Lepik, P. Kotselyabina, E. Kondakova, M. Popova, E. Borzenkova, I. Moiseev, N. Mikhailova, A. Kulagin, Pavlov University, St. Petersburg, RU
- 09:00 - 09:00 **50P - Update of Systematic Reviews and Meta-Analyses Studying the Association Between Antibiotic Use and Clinical Outcomes of Cancer Patients Treated with Immune Checkpoint Inhibitors**
- G. Zalcmán¹, A. Crespin², J. Cervesi², C. Le Bescop², R. Buffet², J. De Gunzburg², P.-A. Bandinelli², ¹Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Université Paris-Diderot, Paris, FR, ²Da Volterra, Paris, FR
- 09:00 - 09:00 **51P - Shortcomings of Immuno oncology (IO) agents application into real world practise due to financial constraints in a resource constrain setting**
- G. Sharat Chandra, M. Singhal, S. Valame, A. Sharma, Indraprastha Apollo Hospital, New Delhi, IN

- 09:00 - 09:00 **52P - Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non small-cell lung carcinoma (NSCLC) : INTEPI, a multicentric retrospective study.**
G. Bilger¹, N. Girard², H. Doubre³, M. Gaj Levra⁴, E. Giroux Leprieur⁵, F. Giraud⁶, C. Decroisette⁷, A. Livartowski², M.-A. Massiani⁸, ¹CH d'Annecy, Annecy, FR, ²Institut Curie, Paris, FR, ³Hopital Foch, Suresnes, FR, ⁴CHU Grenoble Alpes - Site Nord La Tronche, La Tronche, FR, ⁵Hopital Ambroise Pare AP-HP, Boulogne-Billancourt, FR, ⁶Hôpital Cochin, Paris, FR, ⁷Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, ⁸Hopital René Huguenin - Institut Curie, Saint-Cloud, FR
- 09:00 - 09:00 **53P - Studying autoimmune diseases with Thymic Epithelial Tumors (TET): real-world insight from RYTHMIC**
J.C. Benitez¹, M.-E. Boucher¹, E. Dansin², M. Kerjouan³, I. Bigay-Game⁴, E. Pichon⁵, F. Thillays⁶, P.E. Falcoz⁷, S. Lyubimova⁸, Y. Oulhouir⁹, F. Calcagno¹⁰, L. Thiberville¹¹, C. Clément-Duchêne¹², F. Morin¹³, P. Missy¹³, P. Thomas¹⁴, J. Maury¹⁵, T. Molina¹⁶, N. Girard¹⁵, B. Besse¹⁷, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Centre Oscar Lambret, Lille, FR, ³Centre Hospitalier Universitaire de Rennes, Rennes, FR, ⁴Centre Hospitalier Universitaire de Toulouse, Toulouse, FR, ⁵CHRU Hopitaux de Tours - Hopital Bretonneau, Tours, FR, ⁶Institut de Cancérologie de l'ouest,, Rouen, FR, ⁷Centre Hospitalier Universitaire de Strasbourg, Strasbourg, FR, ⁸Centre Hospitalier Universitaire de Montpellier,, Montpellier, FR, ⁹Centre Hospitalier Universitaire de Caen, Caen, FR, ¹⁰Centre Hospitalier Universitaire de Besancon, Besançon, FR, ¹¹Hop. Charles Nicolle, Rouen, FR, ¹²Institut de Cancérologie de Lorraine, Nancy, FR, ¹³French Cooperative Thoracic Intergroup, Paris, FR, ¹⁴CHU Alpes du Sud - Site de Gap, Gap, FR, ¹⁵Institut Curie, Paris, FR, ¹⁶Hôpital Universitaire Necker Enfants et Malade, Paris, FR, ¹⁷Institut Gustave Roussy, Villejuif, FR
- 09:00 - 09:00 **54P - Impact of Comorbidity and Venous Thromboembolism on Outcome in Real-life Non-Small Cell Lung Cancer (NSCLC) patients treated with immune checkpoint inhibition (ICI).**
B. Bjoernhart¹, C. Kristiansen², K. Hansen¹, K. Wedervang³, C. Nyhus², T. Jørgensen¹, J. Herrstedt⁴, T. Schytte¹, ¹OUH - Odense University Hospital, Odense, DK, ²Vejle Hospital Lillebaelt, Vejle, DK, ³Hospital of Southern Jutland, Sønderborg, Aabenraa, DK, ⁴Zealand University Hospital Roskilde and Naestved, Roskilde, DK
- 09:00 - 09:00 **55P - MOREL: Multicenter observational study on treatment and PD-L1 testing in patients (pts) with newly diagnosed stage IV NSCLC in Spain**
B. Rubio-Viqueira¹, M. Majem Tarruella², M.E. Lazaro³, S. Vazquez Estevez⁴, J.F. Cordoba-Ortega⁵, I. Maestu Maiques⁶, J.J. Garcia Gonzalez⁷, A. Blasco Cordellat⁸, J. Valdivia-Bautista⁹, C. Gonzalez Arenas¹⁰, J.M. Sanchez Torres¹¹, ¹Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón, ES, ²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ³Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ⁴Hospital Xeral Calde of Lugo, Lugo, ES, ⁵Hospital Universitario Arnau de Vilanova, Lleida, ES, ⁶Hospital Universitario Doctor Peset, Valencia, ES, ⁷CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, ⁸Hospital General Universitario Valencia, Valencia, ES, ⁹Hospital Universitario Virgen de las Nieves, Granada, ES, ¹⁰MSD - Merck Sharp & Dohme Española S.A., Madrid, ES, ¹¹Hospital

Universitario de La Princesa, Madrid, ES

- 09:00 - 09:00 **56P - Efficacy and safety of nivolumab (Nivo) in recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): A Real-World Data study.**
J.J. Soto Castillo, J. Esteban Villarrubia, P. Alvarez Ballesteros, P. Garrido Lopez, A. Soria Rivas, Hospital Universitario Ramon y Cajal, Madrid, ES
- 09:00 - 09:00 **57P - The efficacy and safety of pembrolizumab in advanced cervical cancer—A real world treatment study**
I. Browne¹, S. Chew¹, D. Fennelly², J. Crown², H. Murray², R. Rahman³, J. Mccaffrey¹, C. Kelly¹, N. Osman Ibrahim⁴, ¹The Mater Misericordiae University Hospital, Dublin, IE, ²St Vincents University Hospital, Dublin, IE, ³St James Hospital, Dublin, IE, ⁴University Hospital Limerick, Limerick, IE
- 09:00 - 09:00 **58P - Real world data of incidence of Immune Related Toxicities with single agent Immuno Oncology drugs at a single center**
G. Sharat Chandra, M. Singhal, A. Sharma, S. Valame, D. Panda, C. Khatri, Indraprastha Apollo Hospital, New Delhi, IN
- 09:00 - 09:00 **59P - Real World Data of Immunotherapy in patients over 65 years old with lung cancer**
B. Nuñez-Garcia¹, Y. Garitaonaindía Díaz², M. Martinez-Cutillas¹, M. Blanco¹, R. Aguado¹, A. Morito Aguilar², C. Traseira¹, G. Visedo³, V. Calvo¹, F. Franco¹, M. Provencio Pulla³, ¹Puerta de Hierro University Hospital, Madrid, ES, ²Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, ³Hospital Puerta de Hierro-Majadahonda, Madrid, ES
- 09:00 - 09:00 **60P - Real world experience of Immunotherapy in elderly cancer patients in a UK cancer centre.**
S. Mirza¹, F. Haque², S. Hodgson², M. Lind², A. Maraveyas³, V. Brown², ¹York Hospital, York, GB, ²Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Cottingham, GB, ³NHS, Cottingham, GB
- 09:00 - 09:00 **61P - Immune Check Point Inhibitors (ICIs) in Cancer Therapy: An Experience from the Resource Poor and Developing Country.**
M. Naseer, A. Patel, A. Anand, H. Panchal, S. Parikh, K. Sajjan, I. Madabhavi, A. Pareek, Gujarat Cancer Research Institute, Ahmedabad, IN
- 09:00 - 09:00 **Therapeutic development**
- 09:00 - 09:00 **66P - Tislelizumab Plus Chemotherapy as First-line Treatment for Lung Cancer in Chinese Patients**
Z. Wang¹, J. Zhao², Z. Ma³, J. Cui⁴, Y. Shu⁵, Z. Liu⁶, Y. Cheng⁷, S. Leaw⁸, Y. Wu⁸, Y. Ma⁸, W. Tan⁸, J. Wang¹, ¹National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Department of Thoracic

Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, CN, ³Henan Cancer Hospital, Zhengzhou, CN, ⁴First Hospital of Jilin University, Changchun, CN, ⁵Jiangsu Province Hospital, Nanjing, CN, ⁶Capital Medical University, Beijing, CN, ⁷Jilin Cancer Hospital, Changchun, CN, ⁸BeiGene (Beijing) Co., Ltd., Beijing, CN

09:00 - 09:00

67P - Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as 1L treatment for advanced NSCLC in CheckMate 227 Part 1

J. Brahmer¹, T.-E. Ciuleanu², M. Schenker³, C. Audigier-Valette⁴, B. Zurawski⁵, H. Linardou⁶, S.-W. Kim⁷, G. Otterson⁸, P. Salman⁹, E. De La Mora Jimenez¹⁰, K. Lesniewski-Kmak¹¹, S. Ahmed¹², I. Albert¹³, F. Barlesi¹⁴, K. Feeney¹⁵, N. Frickhofen¹⁶, A. Li¹⁷, P. Sun¹⁷, M. Hellmann¹⁸, ¹Johns Hopkins Hospital, Baltimore, US, ²The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO, ³Centrul de Oncologie Sf. Nectarie Craiova, Craiova, RO, ⁴Hôpital Sainte-Musse, Toulon, FR, ⁵Centrum Onkologii w Bydgoszczy, Bydgoszcz, PL, ⁶Metropolitan Hospital, Athens, GR, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁸Ohio State Univ Medical Center, Columbus, US, ⁹FALP - Fundacion Arturo Lopez Perez - Instituto Oncologico, Providencia, CL, ¹⁰Pfizer Mexico, Ciudad de Mexico, MX, ¹¹Oddzial Onkologii I Radioterapii Szpital Morski Im. Pck, Gdynia, PL, ¹²University Hospitals of Leicester, Leicester, GB, ¹³Matrai Gyogyintezet, Matrahaza, HU, ¹⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁵St John of God Murdoch Hospital, Perth, AU, ¹⁶University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, DE, ¹⁷Bristol Myers Squibb, Princeton, US, ¹⁸Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

09:00 - 09:00

68P - Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)

A. Tsao¹, P. Baas², A. Nowak³, G. Zalcman⁴, N. Fujimoto⁵, S. Peters⁶, C. Baudalet⁷, P. Aanur⁷, M. Osawa⁸, A. Tendolkar⁷, Y. Feng⁷, J. Sheng⁷, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²The Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, NL, ³Medical School, University of Western Australia and Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, AU, ⁴Bichat-Claude Bernard University Hospital, AP-HP, Université de Paris, Paris, FR, ⁵Okayama Rosai Hospital, Okayama, JP, ⁶Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ⁷Bristol Myers Squibb, Princeton, US, ⁸Bristol Myers Squibb K.K., Tokyo, JP

09:00 - 09:00

69P - Outcomes with Durvalumab and Savolitinib in Metastatic Papillary Renal Cancer (mPRC) according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups

J. Choy¹, C. Suarez Rodriguez², J. Larkin³, P. Patel⁴, B. Perez Valderrama⁵, A. Rodriguez-Vida⁶, H. Glen⁷, F. Thistlethwaite⁸, C. Ralph⁹, G. Srinivasan¹⁰, M.J. Mendez Vidal¹¹, A. Carter¹, C. Tyson¹, A. Prendergast¹, K. Mousa¹, T. Powles¹², B. Szabados¹, ¹Barts Cancer Institute, London, GB, ²Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ³The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁴Nottingham University NHS Trust, Nottingham, GB, ⁵Hospital Universitario Virgen del Rocio, Sevilla, ES, ⁶Hospital del Mar, Barcelona, ES, ⁷BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁸The Christie NHS Foundation Trust, Manchester, GB, ⁹St. James's University Hospital Leeds, Leeds, GB, ¹⁰Broomfield Hospital, Essex, GB, ¹¹Hospital Universitario Reina Sofia, Córdoba, ES,

12St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

- 09:00 - 09:00 **70P - Treatment patterns and overall survival (OS) in patients with advanced BRAF mutant (mt) melanoma treated with immunotherapy and targeted therapy (TT) in a real-world setting**
M. Atkins¹, C. Julian², M. Secrest², J. Lee², A. Abajo³, E. Mckenna², ¹Georgetown Lombardi Comprehensive Cancer Center, Washington, US, ²Genentech, Inc, South San Francisco, US, ³F. Hoffmann-La Roche Ltd, Basel, CH
- 09:00 - 09:00 **71P - A Phase 2 study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results**
D. Zandberg¹, R. Ferris², D. Laux³, R. Mehra⁴, L. Nabell⁵, J. Kaczmar⁶, M. Gibson⁷, Y.J. Kim⁷, P. Neupane⁸, J. Bauman⁹, R. Julian⁹, D. Adkins¹⁰, E. Cohen¹¹, B. Burtneess¹², C. Bermingham¹³, A. Dupage¹³, A. Desbien¹³, A. Loi¹³, D. Nuyten¹³, N. Saba¹⁴, ¹University of Pittsburgh Medical Center, Pittsburgh, US, ²University of Pittsburgh Cancer Institute, Pittsburgh, US, ³University of Iowa, Iowa City, US, ⁴University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, US, ⁵University of Alabama at Birmingham, Birmingham, US, ⁶MUSC Hollings Cancer Center, Charleston, US, ⁷University of Vanderbilt Medical Center, Nashville, US, ⁸University of Kansas, Westwood, US, ⁹University of Arizona College of Medicine, Tucson, US, ¹⁰Washington University of St. Louis, St. Louis, US, ¹¹Moore's Cancer Center - UC San Diego Health, La Jolla, US, ¹²Yale Cancer Center and Yale School of Medicine, New Haven, US, ¹³Aduro Biotech, Inc., Berkeley, US, ¹⁴Winship Cancer Institute, Emory University,, Atlanta, US
- 09:00 - 09:00 **72P - Single-cell Transcriptomics Identifies Distinct PD-1 Blockade Resistance Landscapes of Tumor Immune Microenvironment Among Skin Cancer Subtypes**
A. Li¹, J. Li¹, S. Wu¹, B. Liang¹, X. Chen¹, D. Gao¹, W. Zhang¹, Y. Yu², X. Tang¹, ¹Guangdong Medical University, Zhanjiang, CN, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN
- 09:00 - 09:00 **73P - αGalCer/Antibody Complexes Targeting EGFR-Tumor-associated iNKT to Restore The Immune Response**
D. Dubreuil¹, A. Pattinac², J. Le Pendu², J.-Y. Douillard³, ¹CEISAM - UMR - CNRS 6230 UFR Sciences et Techniques - University of Nantes, Nantes, FR, ²IMSERM, Nantes, FR, ³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR
- 09:00 - 09:00 **74P - Pivotal Trial 201 Data on Outpatient Administration of Naxitamab (Hu3F8), a Humanized GD2 Targeted Immunotherapy for the Treatment of Refractory/ Relapsed (R/R) High-Risk (HR) Neuroblastoma (NB)**
D. Morgenstern¹, J. Mora², G. Chan³, K. Nysom⁴, M. Bear⁵, L. Worsaae Dalby⁶, S. Lisby⁶, B. Kushner⁷, ¹The Hospital for Sick Children, Toronto, CA, ²Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, ES, ³University of Hong Kong, Hong Kong, Hong Kong, HK, ⁴Rigshospitalet, Copenhagen, DK, ⁵Riley Hospital for Children Division of Pediatric Hematology/Oncology, Indianapolis, US, ⁶Y-mAbs Therapeutics, Hørsholm, DK, ⁷Memorial Sloan Kettering Cancer Center, New York, US

- 09:00 - 09:00 **75P - Efficacy and Updated Safety Results from Pivotal Phase II Trial 201 of Naxitamab (Hu3F8), a Humanized GD2 Targeted Immunotherapy for the Treatment of Refractory/Relapsed (R/R) High-Risk (HR) Neuroblastoma (NB)**
J. Mora¹, G. Chan², D. Morgenstern³, K. Nysom⁴, M. Bear⁵, L. Worsaae Dalby⁶, S. Lisby⁶, B. Kushner⁷, ¹Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, ES, ²University of Hong Kong, Hong Kong, Hong Kong, HK, ³The Hospital for Sick Children, Toronto, CA, ⁴Rigshospitalet, Copenhagen, DK, ⁵Riley Hospital for Children Division of Pediatric Hematology/Oncology, Indianapolis, US, ⁶Y-mAbs Therapeutics, Hørsholm, DK, ⁷Memorial Sloan Kettering Cancer Center, New York, US
- 09:00 - 09:00 **76P - Highly Potent Fully Human Anti-VISTA Antibodies Efficiently Abrogate the Interaction of this New Target Checkpoint Inhibitor to its Different Putative Receptors at Different pH.**
S. Iadonato, E. Tarcha, R. Bader, B. Dutzar, N. Eyde, E. Frazier, D. Jurchen, R. Lance, C. Loomis, K. Lustig, Y. Ovechkina, D. Peckham, J. Posakony, S. Sridhar, M. Xu, T. Guillaudeux, Kineta Inc., Seattle, US
- 09:00 - 09:00 **78P - Cancer immunotherapy: rejuvenation of anti-cancer response by immune checkpoint blockade using novel multifunctional nanoparticle to block CTLA-4 and eliminate ICER**
J. Bodor, NanoSYS Biologics, Prague, CZ
- 09:00 - 09:00 **79P - Statins and immunotherapy: togetherness makes strength. The Potential Effect of Statins on Immunotherapy for NSCLC.**
M. Filetti¹, A. Rossi², M. Piras², B. Taurelli Salimbeni², F. Rizzo², R. Giusti², ¹Sapienza, University of Rome, DPT Digestive and Liver Disease, Digestive Neuroendocrine Unit, Rome, IT, ²Sapienza, University of Rome., Rome, IT
- 09:00 - 09:00 **80P - Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples**
S. Basnet¹, S. Zafar¹, I.M. Launonen¹, D. Quixabeira¹, J.M. Santos¹, O. Hemminki¹, M. Malmstedt¹, V. Cervera-Carrascon², P. Aronen¹, R. Kalliokoski³, R. Havunen¹, A. Rannikko¹, T. Mirtti¹, M. Matikainen¹, A. Kanerva¹, A. Hemminki¹, ¹University of Helsinki, Helsinki, FI, ²University of Helsinki - Faculty of medicine, Helsinki, FI, ³TILT Biotherapeutics Ltd, Helsinki, FI
- 09:00 - 09:00 **81P - Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase 2 trial**
J. Fayette¹, J. Bauman², S. Salas³, D. Colevas⁴, C. Even³, D. Cupissol³, M. Posner⁵, G. Lefebvre⁶, E. Saada-Bouazid⁷, M. Bernadach⁸, T. Seiwert⁹, A. Pearson¹⁰, S. Messouak³, S. Cornen³, P. Andre³, F. Rotolo³, A. Boyer-Chammard³, R. Cohen¹¹, ¹Centre Léon Bérard, Lyon, FR, ²Fox Chase Cancer Center, Philadelphia, US, ³Innate Pharma, Marseille, FR, ⁴Stanford University School of Medicine, Stanford, US, ⁵Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, ⁶Centre Oscar Lambret, Lille, FR, ⁷Centre Antoine Lacassagne, Nice Cedex, FR, ⁸Centre jean Perrin, Clermont Ferrand, FR, ⁹Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, ¹⁰The University of Chicago Medical Centre, Illinois, US, ¹¹Abramson Cancer Center, Philadelphia, US

- 09:00 - 09:00 **82P - Novel analysis of *F. nucleatum* subspecies in human CRC tissue and engineering of therapeutic *F. nucleatum* Phage**
L. Ninio-Many¹, N. Buchshtab², I. Vainberg Slutskin², I. Weiner¹, S. Yahav², D. Berko-Ashur², J. Nicenboim², L. Zelcbuch², E. Safyon Gartman², M. Kahan-Hanum², S. Kredor-Russo², M. Golembo², N. Zak², I. Gahali-Sass², S. Puttagunta³, M. Bassan², ¹BiomX, Ness Ziona, IL, ²BiomX LTD, Ness Ziona, IL, ³BiomX Inc, Ness Ziona, IL
- 09:00 - 09:00 **83P - Development of steroid-refractory graft-versus-host disease in a patient with Hodgkin lymphoma treated with nivolumab before allogeneic hematopoietic stem cells transplantation**
B. Anastasiya, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU
- 09:00 - 09:00 **84TiP - Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.**
A. De Caluwe¹, L. Buisseret¹, P. Poortmans², C. Sotiriou¹, D. Larsimont¹, D. Van Gestel¹, A. Laragione¹, A. Desmet¹, R. Van Den Begin¹, C. Philippson¹, D. Eiger¹, M. Piccart¹, E. Romano³, M. Ignatiadis¹, ¹Institute Jules Bordet, Brussels, BE, ²Universitair Ziekenhuis Antwerpen, Antwerp, BE, ³Institut Curie, Paris, FR
- 09:00 - 09:00 **Tumour biology**
- 09:00 - 09:00 **85P - MiRNAome deregulation can contribute to overexpression of immune checkpoints: an epigenetic mechanism of checkpoint inhibitor therapy failure**
V. Halytskiy, Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiev, UA
- 09:00 - 09:00 **86P - HEIH: A novel Immunomodulatory LncRNA Tweaking NK cells and TME in Triple Negative Breast Cancer (TNBC) patients**
H. Nafea¹, R. Youness², K. Abou-Aisha², M. Gad², ¹GUC - German University in Cairo, New Cairo, EG, ²German University in Cairo, Cairo, EG
- 09:00 - 09:00 **87P - An augmented exome/transcriptome-based platform for precision cancer therapy selection, clinical trial matching, and oncology research applications, enabling next-generation composite biomarkers by combining tumor and immune features.**
R. Power, G. Bartha, J. Harris, S. Boyle, E. Levy, P. Milani, P. Tandon, P. Mcnitt, M. Morra, S. Desai, S. Saldivar, M. Clark, C. Haudenschield, J. West, R. Chen, Personalis, Inc., Menlo Park, US
- 09:00 - 09:00 **88P - Identification of Prognostic Radio-Immune-Genetic Profiles in Patients Affected by Glioblastoma**
G. Mazzaschi¹, A. Olivari², S. Dall'Asta², C.A. Lagrasta², C. Frati², D. Madeddu², A. Pavarani², M. Tiseo², M. Michiara², F. Quaini², P. Crafa², ¹University Hospital of Parma, Parma, IT, ²Azienda Ospedaliero-Universitaria di Parma, Parma, IT

- 09:00 - 09:00 **89P - Dissecting tumor-immune interactions in mesothelioma for identifying responders to immune checkpoint blockade**
V. Addala¹, S. Sneddon², I. Dick³, D. Fennell⁴, J. Pearson¹, B. Robinson⁵, J. Creaney⁵, A.-M. Patch¹, N. Waddell¹, ¹QIMR Berghofer Medical Research Institute, Brisbane, AU, ²British Columbia Cancer Agency, Vancouver, CA, ³National Centre for Asbestos Related Disease, Nedlands, AU, ⁴Cancer Research UK Centre Leicester, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, GB, ⁵The University of Western Australia, Perth, AU
- 09:00 - 09:00 **90P - Gastro-sphere Effect on Th17/Treg Diagram, Help or Hindrance?**
A. Rezaletfi¹, G. Solgi², M. Ebrahimi³, ¹Hamedan University of Medical Sciences, Hamadan, IR, ²Hamadan University of Medical Sciences, Hamadan, IR, ³Royan Institute for Stem Cell Biology and Technology, Tehran, IR
- 09:00 - 09:00 **91P - Macrophage-Lineage Transcriptome Networking Reveals SMAD3 as a Novel Regulator for Cancer-Associated Fibroblasts Formation in NSCLC**
P.C.T. Tang¹, T.L. Lee², K.F. To¹, H.Y. Lan³, P.M.K. Tang¹, ¹The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, ²The Chinese University of Hong Kong, Sha Tin, HK, ³The Chinese University of Hong Kong - Li Ka Shing Institute of Health Sciences, Sha Tin, HK
- 09:00 - 09:00 **92P - Characterising the role of HDAC6 in the control of human macrophage IL-10 production**
P. Beer¹, E. Bone¹, H. McElwaine-John², ¹Karus Therapeutics Ltd, Didcot, GB, ²Karus Therapeutics Ltd, Harwell Campus, GB
- 09:00 - 09:00 **93P - CXCL8 и CCL2 production in circulating neutrophils in endometrial cancer**
T. Abakumova, I. Antoneeva, S. Gening, T. Gening, D. Dolgova, Ulyanovsk State University, Ulyanovsk, RU
- 09:00 - 09:00 **94P - New marker of tumor-associated macrophages IL-35 is negatively associated with lymphatic metastasis in colorectal cancer**
E. Kazakova¹, I. Larionova¹, M. Rakina¹, M. Zavyalova², J. Kzhyshkowska³, ¹National Research Tomsk State University, Tomsk, RU, ²Siberian State Medical University, Tomsk, RU, ³Institute of Transfusion Medicine and Immunology, Mannheim, DE
- 09:00 - 09:00 **95P - Immune infiltrate in malignant tumors treated with nivolumab and/or ipilimumab**
K. Joehrens, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE
- 09:00 - 09:00 **96P - Neutrophil-Specific Single-Cell RNA-Sequencing Discovers a Novel Smad3-dependent Immunosuppressor Prdm2 for Promoting NSCLC**
J. Chung¹, T.L. Lee², K.F. To¹, H.Y. Lan³, P.M.K. Tang¹, ¹The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, ²The Chinese University of Hong Kong, Sha Tin, HK, ³The Chinese University of Hong Kong - Li Ka Shing Institute of Health Sciences, Sha Tin, HK

- 09:00 - 09:00 **97TiP - Identification of therapeutic targets in patients with Squamous Cell Carcinoma of the Head and Neck who progress on or after anti-PD-(L)1 therapy - A IMMUcan sub-project**
A. Van Der Elst¹, M. Morfouace², H. Hong³, R. Liechti⁴, J.-P. Machiels⁵, ¹UCLouvain Brussels Woluwe, Brussels, BE, ²EORTC, Brussels, BE, ³Merck, Darmstadt, DE, ⁴SIB Swiss Institute of Bioinformatics, Lausanne, CH, ⁵Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE
- 09:00 - 09:00 **General interest**
- 09:00 - 09:00 **98P - Low Prognostic Nutritional Index is Independently Associated with Poorer Survival in Patients Receiving Immune Checkpoint Inhibitors**
D.C. Guven, O.H. Aktepe, H. Taban, B.Y. Aktas, G. Guner, H.C. Yildirim, T.K. Sahin, M.S. Aksun, O. Dizdar, S. Aksoy, M. Erman, S. Yalcin, S. Kilickap, Hacettepe University Oncology Hospital, Ankara, TR
- 09:00 - 09:00 **99P - The Association Between Antibiotic Use and Survival in Renal Cell Carcinoma Patients Treated with Nivolumab: A Multi-Center Study**
D.C. Guven¹, R. Acar², E. Yekeduz³, I. Bilgetekin⁴, N. Kose Baytemur⁵, C. Erol⁶, F. Ceylan¹, M.A. Sendur⁶, U. Demirci⁵, Y. Urun³, N. Karadurmus², M. Erman¹, S. Kilickap¹, ¹Hacettepe University Oncology Hospital, Ankara, TR, ²Health Sciences University, Gulhane Training and Research Hospital, Ankara, TR, ³Ankara University Faculty of Medicine, Ankara, TR, ⁴Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TR, ⁵Memorial Ankara Hospital, Ankara, TR, ⁶Ankara Yildirim Beyazit University, Ankara, TR
- 09:00 - 09:00 **100P - Patient-derived tissue cultures of esophagogastric-junction cancer (EGJC) and gastric cancer (GC) - an ex vivo model to study individual response of immunotherapy.**
J. Körfer¹, M. Hußtege¹, I. Gockel², A. Monecke², G. Schumacher³, A. Weimann⁴, K. Winter⁵, I. Bechmann⁵, F. Lordick⁶, S. Kallendrusch⁵, ¹UCCL - Universitätsklinikum Leipzig - Universitäres Krebszentrum, Leipzig, DE, ²University Medicine Leipzig, Leipzig, DE, ³Hospital Braunschweig, Braunschweig, DE, ⁴Hospital St. Georg, Leipzig, DE, ⁵Institute for Anatomy, Leipzig, DE, ⁶Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE
- 09:00 - 09:00 **101P - Knocking Down of Cystathionine-γ-lyase (CSE) in Breast Cancer alters PD-L1 Expression Pattern through Tuning CCAT1/let-7a ceRNAs circuit**
N. Selem, R. Youness, M. Gad, German University in Cairo, Cairo, EG
- 09:00 - 09:00 **102P - TNFa and IL-2 armed adenovirus promotes abscopal effect in mice treated with anti-PD-1 immunotherapy**
D. Quixabeira¹, V. Cervera-Carrascon², J.M. Santos¹, R. Havunen¹, A. Hemminki¹, ¹University of Helsinki, Helsinki, FI, ²University of Helsinki - Faculty of medicine, Helsinki, FI

09:00 - 09:00 **103P - Temporospatial heterogeneity in metastatic colorectal cancer (mCRC)**

C. Fountzilas¹, A. Witkiewicz², J. Muhitch¹, S. Abrams¹, E. Knudsen², S. Mukherjee¹, D. Bajor³, J. Saltzman³, K. Wang¹, R. Iyer¹, P. Kalinski¹, P. Boland⁴, ¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ²University of Texas Southwestern Medical Center at Dallas, Dallas, US, ³Case Comprehensive Cancer Center, Cleveland, US, ⁴Rutgers Cancer Institute of New Jersey, New Brunswick, US

10.12.2020

10:30 - 10:45 **Type: Opening session** **Channel 1**
Title: Welcome to the Congress

11:00 - 12:20 **Type: Educational session** **Channel 1**
Title: Future of adjuvant and neoadjuvant treatment
Moderation: Christian Blank, NL

11:00 - 11:15 **The current role for adjuvant and neoadjuvant therapy**
Y. Loriot, Institut Gustave Roussy, Villejuif, FR

11:15 - 11:30 **Ongoing randomised adjuvant and neoadjuvant trials and how they may change the landscape**
C. Blank, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

11:30 - 11:45 **Path CR and MPR as surrogate endpoints for survival endpoint**
M. Kockx, HistoGeneX, Wilrijk, BE

11:45 - 12:00 **Biomarker research from neoadjuvant trials**
I. Duran Martinez, HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES

12:00 - 12:16 **General discussion/Q&A**

11:00 - 12:20 **Type: Educational session** **Channel 2**
Title: RNA signatures
Moderation: Kevin Harrington, GB; Anna Obenauf, AT

11:00 - 11:15 **Using RNA signatures to inform cancer therapy**
N. Mcgranahan, UCL Cancer Institute/Paul O'Gorman Building, London, GB

11:15 - 11:30 **RNA signatures in head and neck cancers**
T. Seiwert, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US

11:30 - 11:45 **RNA signatures in cutaneous malignancies**
J. Becker, University Hospital of Essen, Essen, DE

11:45 - 12:00 **Using RNA signatures to understand immune evasion in targeted therapy-resistant cancer**
A. Obenauf, Research Institute of Molecular Pathology, Vienna, AT

12:00 - 12:16 **General discussion/Q&A**

11:00 - 12:20	Type: Educational session Title: What's new in brain tumours Moderation: Michael Platten, DE; Anna Sophie Berghoff, AT	Channel 3
11:00 - 11:15	Immunotherapy and the immune privilege of the CNS <u>L. Bunse</u> , German Cancer Research Center, Heidelberg, DE	
11:15 - 11:30	CAR T and CAR NK cells for brain tumors <u>H.G. Wirsching</u> , UZH - University of Zurich - Irchel Campus, Zurich, CH	
11:30 - 11:45	Immunotherapy combination trials for gliomas <u>A.S. Berghoff</u> , Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT	
11:45 - 12:00	Immunotherapies in brain metastases and leptomeningeal disease: Novel concepts <u>A. Boire</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
12:00 - 12:16	General discussion/Q&A	
12:35 - 13:35	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 1	Channel 1
13:50 - 15:00	Type: Proffered Paper session Title: Proffered Paper session Moderation: Alessandra Curioni, CH	Channel 1
13:50 - 14:02	10 - Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy <u>T. Powles</u> ¹ , <u>Z.J. Assaf</u> ² , <u>N. Davarpanah</u> ² , <u>M. Hussain</u> ³ , <u>S. Oudard</u> ⁴ , <u>J. Gschwend</u> ⁵ , <u>P. Albers</u> ⁶ , <u>D. Castellano</u> ⁷ , <u>H. Nishiyama</u> ⁸ , <u>S. Daneshmand</u> ⁹ , <u>P. Grivas</u> ¹⁰ , <u>S. Sharma</u> ¹¹ , <u>H. Sethi</u> ¹¹ , <u>A. Aleshin</u> ¹¹ , <u>J. Zhang</u> ¹² , <u>V. Degaonkar</u> ² , <u>C. Bais</u> ² , <u>C. Carter</u> ² , <u>J. Bellmunt</u> ¹³ , <u>S. Mariathasan</u> ² , ¹ St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ² Genentech, Inc., South San Francisco, US, ³ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, US, ⁴ Georges Pompidou European Hospital, University of Paris, Paris, FR, ⁵ Rechts der Isar Hospital, Department of Urology, Technical University Hospital, München, DE, ⁶ Heinrich-Heine University Düsseldorf, Medical Faculty, Department of Urology, University Hospital Düsseldorf, Düsseldorf, DE, ⁷ University Hospital 12 de Octubre, Medical Oncology Department CIBER-ONC, Madrid, ES, ⁸ Department of Urology, Faculty of Medicine University of Tsukuba, Ibaraki, JP, ⁹ USC Norris Comprehensive Cancer Center, Los Angeles, US, ¹⁰ University of Washington, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, US, ¹¹ Natera, San Carlos, US, ¹² Hoffmann-La Roche Ltd., Mississauga, CA, ¹³ Beth Israel Deaconess Medical Center and PSMAR-IMIM Lab, Harvard Medical School, Boston, US	
14:02 - 14:12	Invited Discussant 10 <u>L. Mazzearella</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	

14:12 - 14:22 **Q&A and live discussion**

14:22 - 14:34 **LBA1 - First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743**

A. Scherpereel¹, S. Antonia², Y. Bautista³, F. Grossi⁴, D. Kowalski⁵, G. Zalcman⁶, A. Nowak⁷, N. Fujimoto⁸, S. Peters⁹, A. Tsao¹⁰, A. Mansfield¹¹, S. Popat¹², X. Sun¹³, B. Padilla¹³, P. Aanur¹⁴, M. Daumont¹⁵, B. Bennett¹⁶, M. McKenna¹⁷, P. Baas¹⁸, ¹DRC / CHRU of Lille, Lille, FR, ²H. Lee Moffitt Cancer Center, Tampa, US, ³Centro Médico Nacional Siglo XXI, Mexico City, MX, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, IT, ⁵Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁶Bichat-Claude Bernard University Hospital, AP-HP, Université de Paris, Paris, FR, ⁷Medical School, University of Western Australia and Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, AU, ⁸Okayama Rosai Hospital, Okayama, Okayama, JP, ⁹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹⁰MD Anderson Cancer Center, Houston, US, ¹¹Mayo Clinic, Rochester, US, ¹²Royal Marsden Hospital; Institute of Cancer Research, London, GB, ¹³Adelphi Values, Boston, US, ¹⁴Bristol Myers Squibb, Princeton, US, ¹⁵Bristol Myers Squibb, Braine-l'Alleud, BE, ¹⁶Bristol Myers Squibb, Uxbridge, GB, ¹⁷Health Outcomes Solutions, London, GB, ¹⁸The Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, NL

14:34 - 14:44 **Invited Discussant LBA1**

A. Curioni, University Hospital Zürich, Zurich, CH

14:44 - 14:54 **Q&A live discussion**

13:50 - 15:10 **Type: Educational session** **Channel 2**
Title: Immune metabolic regulations
Moderation: Michele Teng, AU; Per Thor Straten, DK

13:50 - 14:05 **Stress-glucocorticoid axis in affecting cancer immunity**
Y. Ma, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN

14:05 - 14:20 **Impact of exercise on anti-tumor T-cell mediated immunity**
P.T. Straten, University of Copenhagen, Copenhagen, DK

14:20 - 14:35 **Adenosine pathway in the TME**
M. Teng, QIMR Berghofer Medical Research Institute, Brisbane, AU

14:35 - 14:50 **Glutamine blockade and cancer immunotherapy**
J. Powell, Johns Hopkins Hospital, Baltimore, US

14:50 - 15:06 **General discussion/Q&A**

13:50 - 15:10 **Type: Educational session** **Channel 3**
Title: Immuno-oncology in the context of other anticancer treatment
Moderation: Marka Crittenden, US; Alan Melcher, GB

13:50 - 14:05 **Immunotherapy and innate immune activators**
A. Melcher, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

14:05 - 14:20 **Immunotherapy and radiation therapy**
M. Crittenden, The Oregon Clinic at Providence Portland Medical Center, Portland, US

14:20 - 14:35 **Neoadjuvant immunotherapy and surgery**
C. Zuur, The Netherlands Cancer Institute, Amsterdam, NL

14:35 - 14:50 **Immunotherapy and chemotherapy**
L. Emens, UPMC Hillman Cancer Center, Pittsburgh, US

14:50 - 15:06 **General discussion/Q&A**

15:25 - 16:45 **Type: Educational session** **Channel 1**
Title: What's new in gastrointestinal cancers
Moderation: Aurélien Marabelle, FR; Denis Leonardo Jardim, BR

15:25 - 15:40 **CLEVER-1 a new immune checkpoint target with activity in GI cancers**
P. Bono, Terveystalo Helsinki Kamppi, Helsinki, FI

15:40 - 15:55 **ADP-A2AFP SPEAR transgenic T-cell therapy against alpha-fetoprotein (AFP) for patients with hepatocellular carcinoma**
R. Finn, UCLA - School of Medicine, Los Angeles, US

15:55 - 16:10 **Targeting TGFb for enhancing the immunotherapy of GI cancers?**
J. Marie, Centre de recherche en cancerologie de Lyon (CRCL), Lyon, FR

16:10 - 16:25 **The value of TMB as a biomarker to select cancers sensitive to anti-PD(L)1**
D.L. Jardim, Hospital Sirio Libanes, Sao Paulo, BR

16:25 - 16:41 **General discussion/Q&A**

15:25 - 16:45 **Type: Educational session** **Channel 2**
Title: What's new in genitourinary cancers
Moderation: Lawrence Fong, US; Russells Pachynski, US

15:25 - 15:40 **Shifting IO to the neoadjuvant setting for GU malignancies**
L. Fong, University of California UCSF - Diabetes Center, San Francisco, US

15:40 - 15:55 **Combining cytotoxic therapies with IO in bladder cancer**
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

15:55 - 16:10 **Sorting through the combinations in RCC**
C. Suarez Rodriguez, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

16:10 - 16:25 **Emerging immunotherapies for prostate cancer**
R. Pachynski, Washington University School of Medicine in St. Louis, St. Louis, US

16:25 - 16:40 **General discussion/Q&A**

15:25 - 16:45	Type: Educational session Title: Targeting the TME with small compounds	Channel 3
15:25 - 15:40	Title to be confirmed	
15:40 - 15:55	Current state of targeting TGFb to enhance anti-tumor immunity <u>D. Schaer</u> , Pfizer, Pearl River, US	
15:55 - 16:10	Selective inhibition of the adenosine 2a receptor with the non-brain penetrant antagonist, EXS21546, provides full restoration of T-cell function and potential for immuno-oncology <u>A. Payne</u> , Exscientia Ltd., Oxford, GB	
16:10 - 16:25	The case for TIGIT as the next important checkpoint inhibitor <u>I. Mellman</u> , Genentech, Inc., South San Francisco, US	
16:25 - 16:41	General Discussion/Q&A	
17:00 - 18:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 2	Channel 1

11.12.2020

10:00 - 11:00 **Type: Educational session** **Channel 1**
Title: IO Highlights of 2020

10:00 - 10:15 **IL4i1, a metabolic immune checkpoint that activated the Aryhidorcarbon receptor and promotes tumor progression**

C. Opitz, German Cancer Research Center, Heidelberg, DE

10:15 - 10:30 **Diversity of dendritic cells in tumors (murine and human)**

10:30 - 10:45 **Endogenous glucocorticoid signalling regulates CD8 T-cell differentiation and development of dysfunction in the tumor microenvironment**

10:45 - 10:57 **Q&A live discussion**

11:00 - 12:20 **Type: Educational session** **Channel 1**
Title: What's new in melanoma and other skin tumours
Moderation: Caroline Robert, FR; Paolo Ascierto, IT

11:00 - 11:15 **Neoadjuvant treatment for melanoma: Benefit and risk**

E. Rozeman, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

11:15 - 11:30 **Circulating tumour DNA during immunotherapy of melanoma: When and how?**

P. Lorigan, The Christie NHS Foundation Trust, Manchester, GB

11:30 - 11:45 **Dynamics of tumour response during immunotherapy: Evaluation in immunotherapy**

P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

11:45 - 12:00 **Translation control and immune checkpoints**

C. Robert, Institut Gustave Roussy, Villejuif, FR

12:00 - 12:16 **General discussion/Q&A**

11:00 - 12:20	Type: Educational session Title: Identifying and targeting tumour antigens Moderation: Marco Donia, DK; Naiyer Rizvi, US	Channel 2
----------------------	--	------------------

11:00 - 11:15	Neoantigen vaccines <u>N. Rizvi</u> , Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US	
11:15 - 11:30	Shared vs private neo-antigens <u>A. Pasetto</u> , Karolinska Institutet - Cancer Center Karolinska (CCK) - OnkPat, K7, Solna, SE	
11:30 - 11:45	Properties of T-cell recognized neoantigens <u>P. Kvistborg</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
11:45 - 12:00	Tumour-antigen specific cell therapies <u>M. Donia</u> , Herlev Hospital - National Center for Cancer Immune Therapy, Herlev, DK	
12:00 - 12:16	General discussion/Q&A	

11:00 - 12:20	Type: Mini Oral session Title: Mini Oral session 1	Channel 3
----------------------	---	------------------

11:00 - 11:05	23MO - (Withdrawn)	
11:05 - 11:10	24MO - Randomized, Multicenter, Open-label Trial of Autologous Cytokine-Induced Killer Cell Immunotherapy plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer: NCT01631357 <u>R. Xiubao</u> ¹ , <u>Q. Gao</u> ² , <u>J. Jiang</u> ³ , <u>J. Zhang</u> ⁴ , <u>X. Song</u> ⁵ , <u>J. Cui</u> ⁶ , <u>Y. Ye</u> ⁷ , <u>Z. Wang</u> ⁸ , <u>H. Yao</u> ⁵ , <u>X. Zhang</u> ⁹ , <u>X. Hao</u> ⁹ , <u>L. Liu</u> ⁹ , ¹ Tianjin Cancer Hospital, Tianjin, CN, ² Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ³ Third Affiliated Hospital of Soochow University, Changzhou, CN, ⁴ Shanxi Bethune Hospital, Taiyuan, CN, ⁵ Third Affiliated Hospital of Kunming Medical University, Kunming, CN, ⁶ First Hospital of Jilin University, Changchun, CN, ⁷ Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fujian, CN, ⁸ Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ⁹ Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN	
11:10 - 11:22	Invited Discussant 23MO and 24MO	
11:22 - 11:37	Q&A and live discussion	

11:37 - 11:42	<p>30MO - ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC)</p> <p><u>Y. Shi</u>¹, L. Wu², X. Yu³, P. Xing¹, J. Zhou⁴, A. Wang⁵, J. Shi⁶, Y. Hu⁷, Z. Wang⁸, G. An⁹, Y. Fang¹⁰, S. Sun¹¹, C. Zhou¹², C. Wang¹³, F. Ye¹⁴, X. Li¹⁵, J. Wang¹⁶, M. Wang¹⁷, Y. Liu¹⁸, Y. Zhao¹⁹, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Hunan Cancer Hospital, Changsha, CN, ³Zhejiang Cancer Hospital, Hangzhou, CN, ⁴First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ⁵Weihai Municipal Hospital, Weihai, CN, ⁶Linyi Cancer Hospital, Linyi, CN, ⁷Chinese People's Liberation Army General Hospital, Beijing, CN, ⁸Peking University Cancer Hospital & Institute, Beijing, CN, ⁹Beijing Chao-Yang Hospital, Beijing, CN, ¹⁰Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN, ¹¹Xuzhou Central Hospital, Xuzhou Medical University, Xuzhou, CN, ¹²Shanghai Pulmonary Hospital, Shanghai, CN, ¹³Tianjin Cancer Hospital, Tianjin Medical University, Tianjin, CN, ¹⁴Department of Medical Oncology, Xiamen, CN, ¹⁵the First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ¹⁶Affiliated Hospital of Jining Medical University, Jining, CN, ¹⁷Peking Union Medical College Hospital, Beijing, CN, ¹⁸Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, CN, ¹⁹Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN</p>
11:42 - 11:47	<p>62MO - A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in locally advanced NSCLC</p> <p><u>J. Lei</u>, X. Yan, J. Zhao, F. Tian, Q. Lu, T. Jiang, Tangdu hospital, The Fourth Military Medical University, Xi'an City, CN</p>
11:47 - 11:59	<p>Invited Discussant 30MO and 62MO</p> <p><u>B. Besse</u>, Institut Gustave Roussy, Villejuif, FR</p>
11:59 - 12:14	<p>Q&A and live discussion</p>
12:35 - 13:35	<p>Type: Industry Satellite Symposium Title: Industry Satellite Symposium 3</p>
Channel 1	

13:50 - 15:10 **Type: Educational session** **Channel 1**
Title: Immunological memory and trained immunity
Moderation: Andreas Lundqvist, SE; Catherine Wu, US

13:50 - 14:05 **Tissue resident memory T-cells in cancer**
F. Mami-Chouaib, Institut Gustave Roussy, Villejuif, FR

14:05 - 14:20 **Neoantigen vaccine generates intratumoral T-cell responses**
C. Wu, Dana-Farber Cancer Institute, Boston, US

14:20 - 14:35 **Clinical responses in immune checkpoint inhibitor-resistant metastasised melanoma treated with adoptive T-cell transfer and DC vaccination**
R. Kiessling, Karolinska Institute, Stockholm, SE

14:35 - 14:50 **Cancer vaccine triggers antiviral-type defences**
J. De Vries, Radboud University Medical Center, Nijmegen, NL

14:50 - 15:06 **General discussion/Q&A**

13:50 - 15:10 **Type: Educational session** **Channel 2**
Title: What's new in lymphoma
Moderation: Sebastian Kobold, DE; Catherine Diefenbach, US

13:50 - 14:05 **Current overview of therapeutic pipeline in lymphoma**
M. Hutchings, Rigshospitalet, University of Copenhagen, Copenhagen, DK

14:05 - 14:20 **T-cell activating antibodies**
C. Diefenbach, NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US

14:20 - 14:35 **On-label use of CAR T-cells**
F. Stenner-Liewen, Universitätsspital Basel, Basel, CH

14:35 - 14:50 **Next generation CAR T-cells**
S. Kobold, LMU Klinikum der Universität München, Munich, DE

14:50 - 15:06 **General discussion/Q&A**

13:50 - 15:10	Type: Educational session Title: What's new in head and neck cancer Moderation: Luca Mazzarella, IT; Caroline Even, FR	Channel 3
----------------------	--	------------------

13:50 - 14:05 **Single cell profiling of H&N tumors**

R. Ferris, University of Pittsburgh Cancer Institute, Pittsburgh, US

14:05 - 14:20 **Preclinical models of H&N immunotherapy**

E. Cohen, Moores Cancer Center - UC San Diego Health, La Jolla, US

14:20 - 14:35 **How to use biomarkers in decision making**

C. Even, Institut Gustave Roussy, Villejuif, FR

14:35 - 14:50 **IO vs EXTREME: How to pick a winner in 2020?**

K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

14:50 - 15:06 **General discussion/Q&A**

15:25 - 16:45	Type: Educational session Title: What's new in lung cancer Moderation: Solange Peters, CH; Alessandra Curioni, CH	Channel 1
----------------------	---	------------------

15:25 - 15:40 **IO in the neo-adjuvant setting**

S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

15:40 - 15:55 **IO and radiotherapy: Rationale and trial development**

S. Demaria, Weill Cornell Medical College, New York, US

15:55 - 16:10 **IO in advanced stage: New combinations**

R.S. Herbst, Yale University School of Medicine, New heaven, US

16:10 - 16:25 **IO in mesothelioma and SCLC: New approaches**

16:25 - 16:41 **General discussion/Q&A**

15:25 - 16:45	Type: Educational session Title: Tumour microenvironment Moderation: Maija Hollmén, FI; Samra Turajlic, GB	Channel 2
----------------------	--	------------------

15:25 - 15:40 **The role of myeloid cells in shaping TME**

M. Hollmén, University of Turku, Turku, FI

15:40 - 15:55 **Metabolic interactions between tumour cells and T-cells as targets to improve cancer immunotherapy**

G. Delgoffe, University of Pittsburgh Cancer Institute, Pittsburgh, US

15:55 - 16:10 **Hepatic stellate cells suppress NK cell sustained breast cancer dormancy**

A. Correia, Universität Basel, Basel, CH

16:10 - 16:25 **The role of cancer associated fibroblasts**

E. Sahai, Francis Crick Institute, London, GB

16:25 - 16:41 **General discussion/Q&A**

15:25 - 16:45	Type: Educational session Title: Novel immunotherapeutic platforms	Channel 3
----------------------	---	------------------

15:25 - 15:40 **At the intersection of science and engineering: Novel platform approaches to immunotherapy**

D.S. Chen, IGM Biosciences, Mountain View, US

15:40 - 15:55 **Rational STING agonist combination therapy**

S. Carotta, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, AT

15:55 - 16:10 **Inhibition of GARP-TGF- β 1 activation by Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer**

S. Lucas, De Duve Institute UCLouvain, Woluwe-Saint-Lambert, BE

16:10 - 16:25 **Opportunities for antisense oligonucleotide-based therapies within immuno-oncology**

F. Jaschinski, Secarna Pharmaceuticals GmbH&Co.KG, Marburg, DE

16:25 - 16:41 **General discussion/Q&A**

17:00 - 18:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 4	Channel 1
----------------------	---	------------------

12.12.2020

11:00 - 12:20	Type: Educational session Title: What's new in breast & gynaecological cancers Moderation: Bernd Bodenmiller, CH	Channel 1
----------------------	--	------------------

11:00 - 11:15	The single-cell landscape of breast cancer <u>B. Bodenmiller</u> , UZH - University of Zurich - Irchel Campus, Zurich, CH
11:15 - 11:30	Immunotherapy in triple negative breast cancer <u>E. Romano</u> , Institut Curie, Paris, FR
11:30 - 11:45	Exploring the microenvironment of high-grade serous ovarian cancer <u>F. Balkwill</u> , Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, London, GB
11:45 - 12:00	Proteomics to define Immunotherapy targets in ovarian cancer <u>F. Coscia</u> , The Novo Nordisk Foundation Center for Protein Research - University of Copenhagen, Copenhagen, DK
12:00 - 12:16	General discussion/Q&A

11:00 - 12:20	Type: Educational session Title: Interfaces between COVID-19 and immunotherapy in cancer patients	Channel 2
----------------------	--	------------------

11:00 - 11:15	Checkpoint blockade in the era of COVID-19: Pros and cons <u>E. Romano</u> , Institut Curie, Paris, FR
11:15 - 11:30	Cancer treatment in COVID-19 patients <u>M. Garassino</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
11:30 - 11:45	The place of cytokines/vaccines
11:45 - 12:00	Is there a role for jak1/2 inhibitors in patients with severe COVID-19?
12:00 - 12:16	Q&A and live discussion

11:00 - 12:20	Type: Educational session Title: Compartmental biomarker analysis and the management of IO therapy Moderation: Tanja de Gruijl, NL; Etienne Giroux-Leprieur, FR	Channel 3
11:00 - 11:15	Loco-regional vs. systemic biomarkers upon local/intratumoural immune checkpoint blockade <u>T. De Gruijl</u> , Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL	
11:15 - 11:30	Compartmental analysis of T-cell clonal dynamics and prediction of clinical response to immune checkpoint blockade <u>K. Smith</u> , Johns Hopkins University, Baltimore, US	
11:30 - 11:45	Circulating exosomes as prognostic and predictive biomarkers for patients with head and neck cancer <u>M.-N. Theodoraki</u> , University of Ulm, Ulm, DE	
11:45 - 12:00	ctDNA and other soluble plasma-based biomarkers for IO therapy response prediction in lung cancer <u>E. Giroux-Leprieur</u> , Hopital Ambroise Pare, Boulogne-Billancourt, FR	
12:00 - 12:16	General discussion/Q&A	
12:35 - 13:55	Type: Proffered Paper session Title: Mini Oral session 2	Channel 1
12:35 - 12:40	33MO - A Phase I Study of SHC014748M Capsules in Patients with Relapsed or Refractory indolent B-cell Malignancies <u>W. Xu</u> ¹ , J. Qian ² , L. Wang ¹ , H. Zhu ¹ , K. Zhou ³ , X. Xu ⁴ , F. Zhou ⁵ , L. Zhang ⁶ , X. Zhang ⁷ , Z. Wang ⁷ , J. Jin ² , J. Li ¹ , ¹ The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ² The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, CN, ³ Henan Cancer Hospital, Zhengzhou, CN, ⁴ Nantong Cancer Hospital, Nantong, CN, ⁵ Zhongnan Hospital of Wuhan University, Wuhan, CN, ⁶ Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, CN, ⁷ Nanjing Sanhome Co., Ltd, Nanjing, CN	
12:40 - 12:45	63MO - TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironment (TME) and drives antitumor responses in Human PapillomaVirus (HPV)+ malignancies <u>C. Le Tourneau</u> ¹ , P. Cassier ² , F. Rolland ³ , S. Salas ⁴ , J.-M. Limacher ⁵ , O. Capitain ⁶ , O. Lantz ¹ , A. Lalanne ¹ , C. Ekwegbara ¹ , A. Tavernaro ⁷ , H. Makhoulfi ⁷ , K. Bendjama ⁷ , J.-P. Delord ⁸ , ¹ Institut Curie, Paris, FR, ² Centre Léon Bérard, Lyon, FR, ³ Institut de Cancérologie de l'Ouest, Saint Herblain, FR, ⁴ AP-HM, Marseille, FR, ⁵ Hôpitaux Civils de Colmar, Colmar, FR, ⁶ Institut de Cancérologie de l'Ouest, Angers, FR, ⁷ Transgene SA, Illkirch-Graffenstaden, FR, ⁸ IUCT Oncopole, Toulouse, FR	

12:45 - 12:57 **Invited Discussant 33MO and 62MO**

12:57 - 13:12 **Q&A live discussion**

13:12 - 13:17 **64MO - A Phase (ph) 2, Multi-Center Study of the Safety and Efficacy of tebentafusp (tebe) (IMCgp100) in Patients (pts) with Metastatic Uveal Melanoma (mUM)**

J. Sacco¹, R. Carvajal², M. O. Butler³, A. Shoushtari⁴, J. C. Hassel⁵, A. Ikeguchi⁶, L. Hernandez-Aya⁷, P. Nathan⁸, O. Hamid⁹, J.M. Piulats Rodriguez¹⁰, M. Rieth¹¹, D. Johnson¹², J. J. Luke¹³, E. Espinosa¹⁴, S. Leyvraz¹⁵, H. Goodall¹⁶, C. Holland¹⁷, S. Abdullah¹⁷, T. Sato¹⁸, ¹Clatterbridge Cancer Center - NHS Foundation Trust, Wirral, GB, ²Memorial Sloan-Kettering Cancer Center, New York, US, ³Princess Margaret Cancer Center, Toronto, CA, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ⁶University of Oklahoma, Oklahoma City, US, ⁷Washington University School of Medicine, Saint Louis, US, ⁸Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB, ⁹The Angeles Clinic and Research Institute, Los Angeles, US, ¹⁰ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ¹¹University of Colorado, Aurora, US, ¹²Vanderbilt University, Nashville, US, ¹³University of Pittsburgh Cancer Institute, Pittsburgh, US, ¹⁴Hospital Universitario La Paz, Madrid, ES, ¹⁵Charité - Universitätsmedizin Berlin, Berlin, DE, ¹⁶Immunocore Ltd, Abingdon-on-Thames, GB, ¹⁷Immunocore LLC, Rockville, US, ¹⁸Jefferson University, Philadelphia, US

13:17 - 13:22 **65MO - A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma**

J.K. Schwarze¹, C. Bertels², G. Awada³, J. Tijtgaat⁴, S. Tuyaerts⁵, L. Cras³, F. Vaeyens⁶, A.-M. Vanbinst⁶, H. Everaert³, A. Michotte³, B. Caljon³, C. Olsen⁷, T. Janssen⁷, S. Van Dooren³, R. Forsyth³, J. Duerinck³, B. Neyns⁴, ¹UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ²UZ Brussel, Jette, BE, ³Universitair Ziekenhuis Brussel, Brussels, BE, ⁴Vrije Universiteit Brussel-Campus Jette, Brussels, BE, ⁵KU Leuven - VIB Campus Gasthuisberg, Leuven, BE, ⁶Universitair Ziekenhuis Brussel, Jette, BE, ⁷Vrije Universiteit Brussel - Universitair Ziekenhuis Brussel, Brussels, BE

13:22 - 13:34 **Invited Discussant 64MO and 65MO**

13:34 - 13:49 **Q&A and live discussion**

12:35 - 13:55	Type: Educational session Title: B-cell biology Moderation: Göran Jönsson, SE	Channel 2
12:35 - 12:50	Basic concepts of intratumoral B-cells <u>B. Nelson</u> , BC Cancer Agency, Vancouver, CA	
12:50 - 13:05	The role of B-cells and tertiary lymphoid structures in response to immune checkpoint inhibitors <u>G. Jönsson</u> , Lund University, Lund, SE	
13:05 - 13:20	B-cell immunity and immune evasion in human cancers <u>C. Mauri</u> , UCL Cancer Institute - UCL - London's Global University, London, GB	
13:20 - 13:35	Regulatory B-cells and resistance to immunotherapy <u>Y. Pylayeva-Gupta</u> , University of North Carolina - Chapel Hill, Chapel Hill, US	
13:35 - 13:51	General discussion/Q&A	